|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8007830||ORGANON||Granule formation|| |
(10 months ago)
Singulair is owned by Organon.
Singulair contains Montelukast Sodium.
Singulair has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Singulair are:
Singulair was authorised for market use on 26 July, 2002.
Singulair is available in granule;oral dosage forms.
The generics of Singulair are possible to be released after 24 October, 2022.
Market Authorisation Date: 26 July, 2002
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic